29 January 2018

Notice of Results

 

London, UK, 29 January 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, with an initial focus on addressing anaemia associated with renal and gastrointestinal disorders, announces it will report its results for the year ended 31 December 2017 on Wednesday, 28 February 2018.

Carl Sterritt, Chief Executive Officer and Karl Keegan, Chief Financial Officer, will host a presentation and conference call for analysts at 9.30 a.m. GMT on the morning of the results in the Guildhall Room at 85 Gresham Street, London EC2V 7NQ.

-Ends-

 

For further information please contact:

 

Shield Therapeutics plc

+44 (0) 207 186 8500

Karl Keegan, Chief Financial Officer

Fleur Wood, Director, Investor Relations

 

 

Nominated Adviser and Joint Broker

+44 (0)20 3100 2222

Liberum Capital Limited

 

Christopher Britton/Steve Pearce

 

Joint Broker                                                                                                

+ 44 (0)20 7418 8900

Peel Hunt LLP

 

James Steel/Christopher Golden

 

 

Financial PR Adviser

+44 (0)203 709 5700

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal

shieldtherapeutics@consilium-comms.com

 

US Investor Relations

+1 (212) 867 1762

Lazar Partners

 

Fern Lazar/David Carey

 

 

About Shield Therapeutics plc

Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs.  Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com.

 


Back to previous page